

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KUANGCHI SCIENCE LIMITED**

**光啟科學有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 439)**

**CHANGE OF EXECUTIVE DIRECTORS  
AND  
NON-COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES**

**RESIGNATION OF EXECUTIVE DIRECTORS**

The board of directors (“**Board**”) of KuangChi Science Limited (the “**Company**”) hereby announces that Dr. Liu Ruopeng, Dr. Luan Lin and Dr. Ji Chunlin have resigned as executive Directors with effect from 10 September 2025 to devote more time to pursue their other business commitments.

Each of Dr. Liu Ruopeng, Dr. Luan Lin and Dr. Ji Chunlin has confirmed that he/she did not have any disagreement with the Board and there is no other matter in relation to his/her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Board would like to express its sincere gratitude to Dr. Liu Ruopeng, Dr. Luan Lin and Dr. Ji Chunlin for their valuable contribution to the Company during their tenure of service.

## APPOINTMENT OF EXECUTIVE DIRECTORS

The Board is pleased to announce that with effect from 10 September 2025:

1. Dr. Liu Weiwen (劉未文博士) (“**Dr. Liu W**”), the existing chief executive officer of the Company, has been appointed as an executive Director of the Company; and
2. Mr. Lin Ge (林鵠先生) (“**Mr. Lin**”), has been appointed as an executive Director of the Company.

*The biographic details of the two executive Directors are as follows:*

### **Dr. Liu Weiwen (劉未文博士)**

Dr. Liu W, aged 38, has been appointed as the chief executive officer of the Company on 5 December 2022. Dr. Liu W joined the Group in 2015 and served at management positions, including a Director of Operation Management Department of Shenzhen KuangChi Space Technology Limited\* (深圳光啟空間技術有限公司) (“**KuangChi Space**”), an indirect wholly owned subsidiary of the Company from January 2020 to November 2022, and a Project Management Senior Manager of Project Management Department of KuangChi Space from August 2015 to December 2019. Dr. Liu W obtained a doctorate degree of Materials Science and Engineering from University of Delaware, the United States in 2013 and a bachelor’s degree of Materials Science and Engineering from University of Science and Technology of China in 2007. Dr. Liu W has experience in research and development of materials science and engineering, project management, corporate reform, financial management and capital operations.

Dr. Liu W entered into a service contract with the Company for a fixed term of three years commencing from 10 September 2025 and unless terminated by not less than 3 months’ notice in writing served by either party to the other. According to the service contract, Dr. Liu W is entitled to a remuneration of RMB1,200,000 per annum and eligible for a discretionary financial year-end bonus which will be determined with reference to the Group’s performance. His package is determined by the Board based on the recommendation of the remuneration committee of the Company (the “**Remuneration Committee**”), with reference to his duties and responsibilities in the Company, prevailing market rate and the remuneration policy of the Company. His remuneration package is subject to review by the Remuneration Committee and the Board from time to time.

On 22 April 2021, Dr. Liu W obtained a total of 120,000 share options under the share option scheme adopted by the Company on 31 July 2012, pursuant to which Dr. Liu W is entitled to subscribe for 120,000 shares of the Company upon exercise of such share options. As at the date of this announcement, Dr. Liu W did not exercise any share options.

As at the date of this announcement, save as disclosed above, Dr. Liu W (i) does not hold any other position in the Company or other subsidiaries; (ii) did not hold directorship in other listed companies in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any Directors, supervisors, senior management or substantial or controlling Shareholders of the Company; and (iv) does not have any interest in the securities of the Company and its associated corporations within the meaning under Part XV of the SFO.

Save as disclosed above, the Board is not aware of any other matters that need to be brought to the attention of the Shareholders or the Stock Exchange and there is no information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”) in relation to Dr. Liu W’s appointment.

**Mr. Lin Ge (林鵠先生)**

Mr. Lin, aged 41, possesses over sixteen years of experience in business management and administration. Mr. Lin has been employed by the Company since 2025, responsible for the Company’s investment and capital operation matters. Prior to that, Mr. Lin worked at two well-known domestic securities firms in China from 2009 to 2014. From 2014 to 2018, he was employed at the Shenzhen Stock Exchange. From 2018 to 2020, he served at Shenzhen Kuang-Chi Hezhong Technology Limited. From 2020 to 2025, he served at Nanshan Group Co., Ltd.\* (南山集團有限公司).

Mr. Lin obtained a Master of Business Administration degree from University of Poitiers, France in 2009.

Mr. Lin entered into a service contract with the Company for a fixed term of three years commencing from 10 September 2025 and unless terminated by not less than 3 months’ notice in writing served by either party to the other. According to the service contract, Mr. Lin is entitled to a remuneration of HK\$1,200,000 per annum and eligible for a discretionary financial year-end bonus which will be determined with reference to the Group’s performance. His package is determined by the Board based on the recommendation of the Remuneration Committee, with reference to his duties and responsibilities in the Company, prevailing market rate and the remuneration policy of the Company. His remuneration package is subject to review by the Remuneration Committee and the Board from time to time.

As at the date of this announcement, save as disclosed above, Mr. Lin (i) does not hold any other position in the Company or other subsidiaries; (ii) did not hold directorship in other listed companies in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any Directors, supervisors, senior management or substantial or controlling Shareholders of the Company; and (iv) does not have any interest in the securities of the Company and its associated corporations within the meaning under Part XV of the SFO.

Save as disclosed above, the Board is not aware of any other matters that need to be brought to the attention of the Shareholders or the Stock Exchange and there is no information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules in relation to Mr. Lin's appointment.

The Board would like to welcome Dr. Liu W and Mr. Lin in joining the Board.

### **NON-COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES**

Pursuant to the Rule 13.92 of the Listing Rules, the Stock Exchange will not consider diversity to be achieved for a single gender board. Following the resignation of Dr. Luan Lin, the Company has a single gender Board, which does not meet the board diversity requirement under Rule 13.92 of the Listing Rules.

The Company will use its best endeavours to identify and appoint a suitable female candidate as a director to meet the relevant requirement as soon as practicable, in any event within three (3) months from the date of resignation of Dr. Luan Lin. The Company will make further announcement(s) as and when appropriate.

By Order of the Board  
**KuangChi Science Limited**  
**Cheng Chi Chung Kevin**  
*Company Secretary*

Hong Kong, 10 September 2025

*As at the date of this announcement, the Board comprises three executive Directors, namely Dr. Zhang Yangyang, Dr. Liu Weiwen and Mr. Lin Ge; one non-executive Director namely Mr. Li Chiu Ho; and three independent non-executive Directors, namely Dr. Wong Kai Kit, Mr. Choi Wing Koon and Dr. Wu Zhili.*

\* *For identification purposes only*